Short Interest in UCB SA (OTCMKTS:UCBJY) Decreases By 76.3%

UCB SA (OTCMKTS:UCBJY) was the recipient of a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 3,200 shares, a decrease of 76.3% from the March 15th total of 13,500 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 45,200 shares, the short-interest ratio is currently 0.1 days.

UCB Stock Performance

Shares of OTCMKTS:UCBJY traded up $0.22 on Wednesday, hitting $80.10. 79,510 shares of the company were exchanged, compared to its average volume of 43,211. The company’s 50 day moving average price is $92.58 and its two-hundred day moving average price is $94.79. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. UCB has a one year low of $62.90 and a one year high of $106.60.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.